Published in J Clin Pathol on March 01, 1990
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
HIV/HBV Co-Infections: Epidemiology, Natural History, and Treatment: A Review Article. Iran Red Crescent Med J (2011) 0.95
Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch (1997) 0.88
Sexually transmitted hepatitis: a review. Genitourin Med (1992) 0.88
Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis (2004) 0.81
Iron overload in multiply transfused patients who are HIV seropositive. J Clin Pathol (1993) 0.75
Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study. Epidemiol Infect (2006) 0.75
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
Acute and chronic hepatitis revisited. Review by an international group. Lancet (1977) 2.13
Molecular and cellular pathology of hepatitis B. Lab Invest (1985) 1.43
The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology (1987) 1.14
Identification of a dominant immunogenic epitope of the nucleocapsid (HBc) of the hepatitis B virus. J Med Virol (1986) 1.04
Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med (1986) 1.01
Distribution of HBcAg in hepatitis B detected by immunoperoxidase staining with three different preparations of anti-HBc antibodies. J Clin Pathol (1989) 0.95
Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol (1987) 0.91
Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. J Hepatol (1988) 0.87
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A (2000) 5.36
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother (2003) 3.90
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology (1999) 3.16
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
The induction of tolerance to a soluble protein antigen by oral administration. Immunology (1974) 2.50
Carbon monoxide poisoning. BMJ (1999) 2.47
Gastric intramural pH as a predictor of success or failure in weaning patients from mechanical ventilation. Ann Intern Med (1993) 2.29
Infection of a child in Hong Kong by an influenza A H3N2 virus closely related to viruses circulating in European pigs. J Gen Virol (2001) 2.15
Is primary biliary cirrhosis an immune complex disease? Lancet (1977) 2.15
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (1973) 2.15
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology (1994) 2.00
Recent changes among human influenza viruses. Virus Res (2004) 1.98
Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens (1998) 1.96
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet (1975) 1.90
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med (1989) 1.88
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther (1988) 1.73
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol (1996) 1.73
Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet (1997) 1.71
Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut (1981) 1.67
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Methadone maintenance and tuberculosis treatment. BMJ (1996) 1.61
Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet (1980) 1.61
Changing disease patterns in AIDS. BMJ (1991) 1.59
Molecular basis of a bacterial consortium: interspecies catabolism of atrazine. Appl Environ Microbiol (1998) 1.55
Antigenic and genetic diversity among swine influenza A H1N1 and H1N2 viruses in Europe. J Gen Virol (2002) 1.52
Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut (1990) 1.51
Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. Epidemiol Infect (2005) 1.51
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (2006) 1.50
Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut (1981) 1.50
Patterns of cognitive-motor development in children with fetal alcohol syndrome from a community in South Africa. Alcohol Clin Exp Res (2001) 1.49
Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet (1984) 1.49
Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest (1992) 1.48
Definition of chronic fatigue syndrome (CFS) Br J Psychiatry (1991) 1.47
Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology (1997) 1.47
Histrionicotoxins: roentgen-ray analysis of the novel allenic and acetylenie spiroalkaloids isolated from a Colombian frog, Dendrobates histrionicus. Proc Natl Acad Sci U S A (1971) 1.46
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol (1985) 1.43
Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol (1976) 1.43
Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication. J R Soc Med (1987) 1.42
Diagnosis and management of long-standing benign oral ulceration. Laryngoscope (1980) 1.41
Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol (1995) 1.40
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response. Gut (1993) 1.39
Emergence of influenza A H1N2 reassortant viruses in the human population during 2001. Virology (2002) 1.39
Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology (1981) 1.38
A prospective randomised controlled trial of the LMA Supreme vs cuffed tracheal tube as the airway device during percutaneous tracheostomy. Anaesthesia (2014) 1.38
Two clusters of human infection with influenza A/H5N1 virus in the Republic of Azerbaijan, February-March 2006. Euro Surveill (2006) 1.38
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther (2000) 1.37
Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet (1980) 1.36
Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology (1982) 1.36
Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol (1976) 1.35
Interviewing skills of first-year medical students. J Med Educ (1986) 1.34
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 1.33
Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. J Hepatol (1987) 1.33
Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology (1985) 1.32
HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology (1986) 1.31
Genetic variation in hepatitis B virus. Gastroenterology (1992) 1.29
Pathologist variation in reporting cervical borderline epithelial abnormalities and cervical intraepithelial neoplasia. J Clin Pathol (1995) 1.29
Human infection by a swine influenza A (H1N1) virus in Switzerland. Arch Virol (2003) 1.29
Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology (1991) 1.29
HLA-B8, immunoglobulins, and antibody responses in alcohol-related liver disease. J Clin Pathol (1980) 1.28
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol (1986) 1.26
A rapid one-step radiometric assay for hepatitis B surface antigen utilizing monoclonal antibodies. J Immunol Methods (1982) 1.26
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut (2005) 1.26
An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology (1983) 1.25
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut (2005) 1.24
Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ (1997) 1.24
The immune response in hepatic cirrhosis: animal and human studies. Proc R Soc Med (1977) 1.23
Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology (1992) 1.22
Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. J Gen Virol (1999) 1.22
Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N Engl J Med (1979) 1.22
Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis (1993) 1.22
Inducer and suppressor T-cells in hepatitis B virus-induced liver disease. Hepatology (1982) 1.20
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol (2008) 1.19
The mechanism of replication of hepatitis B virus: evidence of asymmetric replication of the two DNA strands. J Med Virol (1984) 1.18
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol (1998) 1.17